BR112017005313A2 - formação de imagem e terapia para inflamação e infecção direcionadas por hsp90 - Google Patents
formação de imagem e terapia para inflamação e infecção direcionadas por hsp90Info
- Publication number
- BR112017005313A2 BR112017005313A2 BR112017005313A BR112017005313A BR112017005313A2 BR 112017005313 A2 BR112017005313 A2 BR 112017005313A2 BR 112017005313 A BR112017005313 A BR 112017005313A BR 112017005313 A BR112017005313 A BR 112017005313A BR 112017005313 A2 BR112017005313 A2 BR 112017005313A2
- Authority
- BR
- Brazil
- Prior art keywords
- infection
- inflammation
- present
- provides
- imaging
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title abstract 8
- 208000015181 infectious disease Diseases 0.000 title abstract 8
- 230000004054 inflammatory process Effects 0.000 title abstract 8
- 238000003384 imaging method Methods 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 7
- 238000012544 monitoring process Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/026—Measuring blood flow
- A61B5/0275—Measuring blood flow using tracers, e.g. dye dilution
- A61B5/02755—Radioactive tracers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Measuring devices for evaluating the respiratory organs
- A61B5/0813—Measurement of pulmonary parameters by tracers, e.g. radioactive tracers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/42—Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
- A61B5/4222—Evaluating particular parts, e.g. particular organs
- A61B5/4255—Intestines, colon or appendix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
- A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/032—Transmission computed tomography [CT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/037—Emission tomography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/44—Constructional features of apparatus for radiation diagnosis
- A61B6/4417—Constructional features of apparatus for radiation diagnosis related to combined acquisition of different diagnostic modalities
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
- A61B6/503—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of the heart
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
- A61B6/5288—Devices using data or image processing specially adapted for radiation diagnosis involving retrospective matching to a physiological signal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/54—Control of apparatus or devices for radiation diagnosis
- A61B6/541—Control of apparatus or devices for radiation diagnosis involving acquisition triggered by a physiological signal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1884—Nanotubes, nanorods or nanowires
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- High Energy & Nuclear Physics (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Nanotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Dentistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
Abstract
a presente invenção fornece novos métodos para formação de imagem de inflamação e infecção e aplicações médicas relacionadas da mesma. em algumas modalidades, a presente invenção fornece um método para o diagnóstico de inflamação e/ou infecção. em algumas modalidades, a presente invenção fornece um método para o tratamento ou prevenção de inflamação e/ou infecção. em algumas modalidades, a presente invenção fornece métodos para monitorar o efeito do tratamento de inflamação e/ou infecção, e/ou métodos para monitorar um regime de tratamento de inflamação e/ou infecção. em algumas modalidades, a presente invenção fornece um método para selecionar indivíduos para um tratamento de inflamação e/ou infecção. em algumas modalidades, a presente invenção fornece um método para determinar a dosagem de um fármaco para o tratamento de inflamação e/ou infecção.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051590P | 2014-09-17 | 2014-09-17 | |
| PCT/US2015/050753 WO2016044629A1 (en) | 2014-09-17 | 2015-09-17 | Hsp90-targeted inflammation and infection imaging and therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017005313A2 true BR112017005313A2 (pt) | 2017-12-05 |
Family
ID=55533863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017005313A BR112017005313A2 (pt) | 2014-09-17 | 2015-09-17 | formação de imagem e terapia para inflamação e infecção direcionadas por hsp90 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10617772B2 (pt) |
| EP (1) | EP3194975A4 (pt) |
| JP (1) | JP6835709B2 (pt) |
| KR (1) | KR20170052687A (pt) |
| CN (2) | CN107110869B (pt) |
| AU (2) | AU2015317632B2 (pt) |
| BR (1) | BR112017005313A2 (pt) |
| CA (1) | CA2961499A1 (pt) |
| EA (1) | EA201790444A1 (pt) |
| MA (1) | MA40535A (pt) |
| MX (1) | MX387627B (pt) |
| WO (1) | WO2016044629A1 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201490230A1 (ru) | 2011-07-08 | 2014-06-30 | Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч | Применение меченых ингибиторов hsp90 |
| WO2015138039A1 (en) | 2013-12-23 | 2015-09-17 | Memorial Sloan-Kettering Cancer Center | Methods and reagents for radiolabeling |
| MX387627B (es) * | 2014-09-17 | 2025-03-18 | Memorial Sloan Kettering Cancer Center | Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia |
| US11857352B2 (en) | 2016-09-06 | 2024-01-02 | The Research Foundation For The State University Of New York | Positron imaging tomography imaging agent composition and method for bacterial infection |
| LT3483164T (lt) | 2017-03-20 | 2020-05-11 | Forma Therapeutics, Inc. | Pirolpirolo kompozicijos kaip piruvato kinazės (pkr) aktyvatoriai |
| EP3852791B1 (en) | 2018-09-19 | 2024-07-03 | Novo Nordisk Health Care AG | Activating pyruvate kinase r |
| EP3853206B1 (en) | 2018-09-19 | 2024-04-10 | Novo Nordisk Health Care AG | Treating sickle cell disease with a pyruvate kinase r activating compound |
| HRP20251148T1 (hr) | 2019-09-19 | 2025-11-21 | Novo Nordisk Health Care Ag | Pripravci koji aktiviraju piruvat-kinazu r (pkr) |
| JP7733935B2 (ja) * | 2021-01-28 | 2025-09-04 | イムドファーム インコーポレイテッド | カモスタット及びニクロサミドを含む共結晶、それを含む薬学組成物、及び、その製造方法 |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1437145A1 (en) * | 2003-01-07 | 2004-07-14 | Schering AG | Enhanced scintigraphic imaging agents for imaging of infection and inflammation |
| WO2004097428A1 (en) | 2003-05-01 | 2004-11-11 | University Of Liverpool | Screening method for identifying hsp90 modulators |
| MXPA06002997A (es) | 2003-09-18 | 2007-02-08 | Conforma Therapeutics Corp | Novedosos compuestos heterociclicos como inhibidores- hsp90. |
| US7834181B2 (en) * | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| US9403828B2 (en) * | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| WO2006098761A2 (en) | 2005-03-11 | 2006-09-21 | The Regents Of The University Of Colorado | Hsp90 inhibitors, methods of making and uses therefor |
| JP2008540395A (ja) | 2005-05-03 | 2008-11-20 | ファイザー・インク | アミドレソルシノール化合物 |
| EP2049497A2 (en) | 2005-05-19 | 2009-04-22 | Astex Therapeutics Limited | Pyrimidine derivatives as hsp90 inhibitors |
| WO2006130469A1 (en) * | 2005-05-27 | 2006-12-07 | Oregon Health & Science University | Stimulation of neurite outgrowth by small molecules |
| EA200801968A1 (ru) | 2006-03-11 | 2009-02-27 | Вернэлис (Р&Д) Лтд. | Пирролопиримидиновые производные, используемые в качестве ингибиторов hsp90 |
| WO2007134298A2 (en) | 2006-05-12 | 2007-11-22 | Myriad Genetics, Inc. | Therapeutic compounds and their use in cancer |
| DE102006023336A1 (de) | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
| WO2008005937A2 (en) | 2006-06-30 | 2008-01-10 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases through inhibiton of hsp90 |
| AU2008211729A1 (en) | 2007-02-01 | 2008-08-07 | Astrazeneca Ab | 5,6,7,8-tetrahydropteridine derivatives as HSP90 inhibitors |
| KR101313804B1 (ko) | 2007-03-20 | 2013-10-01 | 쿠리스 인코퍼레이션 | Ｈｓｐ９０ 억제제로서의 융합된 아미노 피리딘 |
| EP2155694B1 (en) | 2007-03-27 | 2012-01-04 | Synta Pharmaceuticals Corp. | Triazinone and diazinone derivatives useful as hsp90 inhibitors |
| SG187502A1 (en) | 2008-02-01 | 2013-02-28 | Takeda Pharmaceutical | Oxim derivatives as hsp90 inhibitors |
| FR2932484B1 (fr) | 2008-06-16 | 2010-06-18 | Sanofi Aventis | Nouveaux derives de pyrroloindole inhibiteurs d'hsp90, compositions les contenant et utilisation |
| BRPI0924107A2 (pt) | 2008-11-28 | 2019-09-24 | Novartis Ag | inibidores de hsp90 para tratamento terapêutico |
| WO2010121963A1 (en) | 2009-04-21 | 2010-10-28 | Nerviano Medical Sciences S.R.L. | Resorcinol derivatives as hsp90 inhibitors |
| NZ713361A (en) | 2009-08-17 | 2017-06-30 | Memorial Sloan Kettering Cancer Center | Heat shock protein binding compounds, compositions, and methods for making and using same |
| JP5941407B2 (ja) | 2009-10-07 | 2016-06-29 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｓｐ９０阻害剤 |
| WO2011060253A2 (en) | 2009-11-13 | 2011-05-19 | Myrexis, Inc. | Methods of treating diseases, pharmaceutical compositions, and pharmaceutical dosage forms |
| US20110201587A1 (en) * | 2010-02-16 | 2011-08-18 | Bio Holding, Inc. | Hsp90 inhibitors and methods of use |
| US8669248B1 (en) | 2010-09-30 | 2014-03-11 | John Montana | Adenine inhibitors of HSP90 |
| CN103596955B (zh) | 2011-04-05 | 2016-11-16 | 索隆-基特林癌症研究协会 | Hsp90抑制剂 |
| JP6266506B2 (ja) * | 2011-04-05 | 2018-01-24 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｓｐ９０阻害物質 |
| US8685966B2 (en) | 2011-04-08 | 2014-04-01 | University Of Kansas | GRP94 inhibitors |
| BR112013027448A2 (pt) | 2011-04-28 | 2020-09-01 | Sloan-Kettering Institute For Cancer Research | terapia de combinação com hsp90 |
| EA201490230A1 (ru) | 2011-07-08 | 2014-06-30 | Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч | Применение меченых ингибиторов hsp90 |
| CN102319240A (zh) * | 2011-07-19 | 2012-01-18 | 厦门大学 | 去乙酰真菌环氧乙酯作为Hsp90抑制剂的应用 |
| WO2014025395A1 (en) | 2012-08-06 | 2014-02-13 | Duke University | Compounds and methods for targeting hsp90 |
| EP2972394A4 (en) * | 2013-03-15 | 2016-11-02 | Sloan Kettering Inst Cancer | HSP90-DESIGNING AND THERAPY |
| SG11201601542SA (en) * | 2013-08-16 | 2016-04-28 | Sloan Kettering Inst Cancer | Selective grp94 inhibitors and uses thereof |
| WO2015138039A1 (en) * | 2013-12-23 | 2015-09-17 | Memorial Sloan-Kettering Cancer Center | Methods and reagents for radiolabeling |
| MA39483A (fr) * | 2014-03-18 | 2015-09-24 | Synta Pharmaceuticals Corp | Agents thérapeutiques cibles |
| MX387627B (es) * | 2014-09-17 | 2025-03-18 | Memorial Sloan Kettering Cancer Center | Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia |
-
2015
- 2015-09-17 MX MX2017003513A patent/MX387627B/es unknown
- 2015-09-17 EP EP15841981.2A patent/EP3194975A4/en not_active Withdrawn
- 2015-09-17 JP JP2017514812A patent/JP6835709B2/ja not_active Expired - Fee Related
- 2015-09-17 EA EA201790444A patent/EA201790444A1/ru unknown
- 2015-09-17 BR BR112017005313A patent/BR112017005313A2/pt not_active Application Discontinuation
- 2015-09-17 CN CN201580062252.XA patent/CN107110869B/zh not_active Expired - Fee Related
- 2015-09-17 WO PCT/US2015/050753 patent/WO2016044629A1/en not_active Ceased
- 2015-09-17 CA CA2961499A patent/CA2961499A1/en active Pending
- 2015-09-17 KR KR1020177010291A patent/KR20170052687A/ko not_active Ceased
- 2015-09-17 US US15/511,701 patent/US10617772B2/en not_active Expired - Fee Related
- 2015-09-17 CN CN202110835845.2A patent/CN113521314A/zh active Pending
- 2015-09-17 AU AU2015317632A patent/AU2015317632B2/en not_active Ceased
- 2015-09-17 MA MA040535A patent/MA40535A/fr unknown
-
2020
- 2020-04-10 US US16/845,372 patent/US11065350B2/en not_active Expired - Fee Related
-
2021
- 2021-06-16 US US17/349,723 patent/US20210308285A1/en not_active Abandoned
-
2022
- 2022-04-07 AU AU2022202337A patent/AU2022202337A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3194975A4 (en) | 2018-05-02 |
| AU2015317632A1 (en) | 2017-04-13 |
| CA2961499A1 (en) | 2016-03-24 |
| CN107110869A (zh) | 2017-08-29 |
| US10617772B2 (en) | 2020-04-14 |
| AU2015317632B2 (en) | 2022-01-13 |
| KR20170052687A (ko) | 2017-05-12 |
| MX387627B (es) | 2025-03-18 |
| MA40535A (fr) | 2016-03-24 |
| CN107110869B (zh) | 2021-08-10 |
| EA201790444A1 (ru) | 2017-08-31 |
| US20200237934A1 (en) | 2020-07-30 |
| JP2017530961A (ja) | 2017-10-19 |
| US20170304470A1 (en) | 2017-10-26 |
| MX2017003513A (es) | 2017-07-28 |
| WO2016044629A1 (en) | 2016-03-24 |
| AU2022202337A1 (en) | 2022-04-28 |
| JP6835709B2 (ja) | 2021-02-24 |
| US11065350B2 (en) | 2021-07-20 |
| CN113521314A (zh) | 2021-10-22 |
| EP3194975A1 (en) | 2017-07-26 |
| US20210308285A1 (en) | 2021-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017005313A2 (pt) | formação de imagem e terapia para inflamação e infecção direcionadas por hsp90 | |
| CY1125213T1 (el) | Μεθοδοι θεραπειας καρκινου του μαστου ar+ | |
| MX2019011117A (es) | Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. | |
| MX2017015186A (es) | Metodos de acondicionamiento de pacientes para tratamiento con linfocitos t. | |
| DOP2017000272A (es) | Métodos de diagnóstico para tratamiento con linfocitos t | |
| MX2021008053A (es) | Metodos para monitorear y terapias para usarse en tratar el cancer. | |
| BR112019008384A2 (pt) | composição farmacêutica, processos para tratamento e seus usos | |
| EP3622407A4 (en) | SYSTEMS AND PROCEDURES FOR PATIENT TREATMENT | |
| EP3242589A4 (en) | Method and apparatus for the measurement of autonomic function for the diagnosis and validation of patient treatments and outcomes | |
| MX387283B (es) | Tratamiento del cancer con tg02. | |
| BR112017006113A8 (pt) | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. | |
| BR112015007758A2 (pt) | dispositivo para um tratamento médico de uma esclera, método para tratar a esclera em um sujeito e método para tratar uma alteração patológica ou doença do olho. | |
| MX2018012493A (es) | Métodos para controlar y tratar el cáncer. | |
| CY1122968T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο | |
| MX392470B (es) | Composición farmacéutica que comprende un péptido wt1 para el tratamiento o prevención de una enfermedad angiogénica. | |
| CY1117438T1 (el) | Μεθοδος για την προληψη και την θεραπευτικη αντιμετωπιση της σηψης | |
| CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| MX2022000107A (es) | Metodos de tratamiento que tienen toxicidad relacionada con farmacos reducida y metodos para identificar la probabilidad de da?o que surja de medicamentos recetados a pacientes. | |
| CY1123696T1 (el) | Φαρμακο για τη θεραπεια των μολυνσεων του διαβητικου ποδιου | |
| BR112015024703A2 (pt) | formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose | |
| CY1118532T1 (el) | Φαρμακευτικη συνθεση για χρηση στη θεραπευτικη αγωγη ή προληψη των ελλειψεων βιταμινων και μεταλλικων αλατων σε ασθενεις που εχουν υποβληθει σε επεμβαση γαστρικης παρακαμψης | |
| MX2017003015A (es) | Metodo para tratar canceres solidos y/o metastasis de los mismos, medicamentos para los mismos, y metodo para predecir el resultado clinico para tratar canceres solidos y/o metastasis de los mismos. | |
| EP3507368A4 (en) | COMPOUNDS FOR THE DETECTION AND TREATMENT OF MYCOPLASMA HYOPNEUMONIAE | |
| BR112017009577A2 (pt) | análogos de pantotenamida | |
| EA201692164A1 (ru) | Лекарственное средство для лечения пациентов с тиннитусом |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |